Endo International and Auxilium Pharmaceuticals have entered into a definitive agreement under which Endo will acquire Auxilium in a deal valued at $2.6 billion. By adding Auxilium’s complementary commercial portfolio, the company says it intends to leverage Auxilium’s leading presence in men’s health, as well as its R&D capabilities and financial resources to accelerate the growth of Xiaflex and Auxilium’s other products. “We are pleased to have reached this ...